




Searching News Database: antidepressant
HSMN NewsFeed - 17 Mar 2021
MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation
MagVenture introduces new solution to improve the ease of use for non-invasive brain stimulation
HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
HSMN NewsFeed - 1 Aug 2019
Neuronetics(R) Announces First TMS Patient Treated Under New Japan Reimbursement Policy
Neuronetics(R) Announces First TMS Patient Treated Under New Japan Reimbursement Policy
HSMN NewsFeed - 27 Mar 2019
FDA Clears the Cervella Cranial Electrotherapy Stimulator for Treatment of Anxiety, Insomnia, and Depression
FDA Clears the Cervella Cranial Electrotherapy Stimulator for Treatment of Anxiety, Insomnia, and Depression
HSMN NewsFeed - 20 Feb 2019
MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
MagVenture, Inc.: Robotic Aid to Drugfree Depression Treatment Receives FDA Clearance
HSMN NewsFeed - 22 Aug 2018
MagVenture, Inc: FDA Clears 3-Minute, Non-Pharmaceutical Depression Treatment
MagVenture, Inc: FDA Clears 3-Minute, Non-Pharmaceutical Depression Treatment
HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
HSMN NewsFeed - 23 Jun 2017
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
Lundbeck and Takeda receive Complete Response Letter from the FDA for Trintellix(R) (vortioxetine) sNDA
HSMN NewsFeed - 1 Aug 2016
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
Orexigen Completes Acquisition of All U.S. Rights to Contrave(R) and Launches U.S. Sales Organization
HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
HSMN NewsFeed - 28 Aug 2015
Therapy System for Treating Major Depressive Disorder Receives FDA Clearance
Therapy System for Treating Major Depressive Disorder Receives FDA Clearance
HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
HSMN NewsFeed - 3 Jun 2014
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
Spinifex Pharmaceuticals Appoints Neuroscience Expert Dr Ronald Marcus as Chief Medical Officer
HSMN NewsFeed - 25 Jul 2013
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
Promentis Pharmaceuticals, Inc. Appoints Industry Veteran Chad Beyer, Ph.D., MBA, as President and CEO
HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
HSMN NewsFeed - 4 Nov 2010
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
Euthymics Bioscience, Inc. Names Biotech Executive Timothy J. Barberich to Board of Directors
HSMN NewsFeed - 10 Aug 2010
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
Labopharm announces U.S. launch of OLEPTRO(TM) for treatment of major depressive disorder in adults
HSMN NewsFeed - 9 Jul 2010
BOTOX(R) Receives First Authorisation in UK as Preventative Treatment in Chronic Migraine
BOTOX(R) Receives First Authorisation in UK as Preventative Treatment in Chronic Migraine
HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
HSMN NewsFeed - 8 Dec 2009
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
HSMN NewsFeed - 30 Nov 2009
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Generalized Anxiety Disorder
HSMN NewsFeed - 11 Sep 2009
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
New Data Show Patients With Chronic Low Back Pain Maintained Pain Reduction on Cymbalta(R)
HSMN NewsFeed - 2 Jun 2009
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
HSMN NewsFeed - 2 Jun 2009
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
Clinical Data, Inc. Announces Positive Results from Second Phase III Trial of Vilazodone for Depression
HSMN NewsFeed - 7 May 2009
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
New Once-Daily RYZOLT(TM) (tramadol HCl extended-release tablets) Now Available in the U.S.
HSMN NewsFeed - 20 Apr 2009
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Commercial Availability of Savella(TM)
HSMN NewsFeed - 7 Apr 2009
IntelGenx Corp. and Cary Pharmaceuticals File NDA for CPI-300 Antidepressant
IntelGenx Corp. and Cary Pharmaceuticals File NDA for CPI-300 Antidepressant
HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
HSMN NewsFeed - 26 Feb 2009
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
HSMN NewsFeed - 10 Dec 2008
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
Study Showed New Episodes of Depression Delayed in People Taking Cymbalta(R)
HSMN NewsFeed - 28 Nov 2008
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
HSMN NewsFeed - 17 Nov 2008
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
Mylan Receives Tentative FDA Approval for the Generic Version of the Antidepressant Effexor XR(R)
HSMN NewsFeed - 22 Oct 2008
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
HSMN NewsFeed - 22 Sep 2008
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression
HSMN NewsFeed - 25 Aug 2008
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
Patients Taking Cymbalta(R) Experienced Reduced Chronic Low Back Pain in New Study
HSMN NewsFeed - 22 Aug 2008
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
Cymbalta Receives European Approval for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 5 Aug 2008
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
HSMN NewsFeed - 30 Jun 2008
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
HSMN NewsFeed - 27 Jun 2008
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
European CHMP Issues Positive Opinion on Cymbalta for the Treatment of Generalised Anxiety Disorder
HSMN NewsFeed - 16 Jun 2008
Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
Mylan Announces Final FDA Approval for Generic Version of Antidepressant Effexor(R)
HSMN NewsFeed - 13 Jun 2008
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
HSMN NewsFeed - 3 Jun 2008
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
New Abbott Aluvia(R) Tablet for Treatment of HIV Available in South Africa
HSMN NewsFeed - 23 May 2008
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
Osmotica Pharmaceutical Receives FDA Approval to Market Novel Forms of Extended Release Venlafaxine HCl
HSMN NewsFeed - 15 May 2008
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
Wyeth's Pristiq, a New Treatment for Major Depressive Disorder in Adults, Now Available in U.S. Pharmacies
HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
HSMN NewsFeed - 7 Apr 2008
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
New Abbott Kaletra(R) (lopinavir/ritonavir) Lower-Strength Tablet for Pediatric Use Approved in Europe
HSMN NewsFeed - 13 Mar 2008
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
Clinical Data, Inc. Initiates Second Pivotal Phase III Study of Vilazodone
HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
HSMN NewsFeed - 12 Dec 2007
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
New Phase 3 Data Showed PRISTIQ Significantly Reduced Symptoms of Major Depressive Disorder Versus Placebo
HSMN NewsFeed - 5 Dec 2007
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
New Data Reinforces the Superiority of Escitalopram Over Duloxetine for Acute Treatment of Depression
HSMN NewsFeed - 30 Nov 2007
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
HSMN NewsFeed - 16 Oct 2007
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
Cortex Names Pierre V. Tran, MD, MMM, Chief Medical Officer and Vice President of Clinical Development
HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
HSMN NewsFeed - 11 Sep 2007
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
Validus Pharmaceuticals Expands Product Portfolio with Acquisition of Bipolar Drug: Equetro(R)
HSMN NewsFeed - 21 Aug 2007
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
HSMN NewsFeed - 20 Aug 2007
New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
New Study Supports Efficacy of Vagus Nerve Stimulation for Treatment-Resistant Depression
HSMN NewsFeed - 10 Jul 2007
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
Noven to Acquire JDS Pharmaceuticals, Expanding Business Model & Broadening Product Pipeline
HSMN NewsFeed - 7 Jun 2007
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
Labopharm Initiates Phase III Clinical Study for Once-Daily Formulation of Trazodone
HSMN NewsFeed - 21 May 2007
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
HSMN NewsFeed - 3 May 2007
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Data Suggest Cymbalta(R) Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
HSMN NewsFeed - 5 Mar 2007
Teva Announces Agreement with Biovail and Anchen Regarding Generic Wellbutrin XL
Teva Announces Agreement with Biovail and Anchen Regarding Generic Wellbutrin XL
HSMN NewsFeed - 1 Feb 2007
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
Anavex Life Sciences Corp. Outlines Its Central Nervous System (CNS) Portfolio of Novel Therapeutics
HSMN NewsFeed - 22 Dec 2006
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
Largest Disease Modification Trial for Parkinson's Disease Completes Enrollment
HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
HSMN NewsFeed - 13 Nov 2006
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
XOPENEX HFA(R) Data Presented at American College of Allergy, Asthma and Immunology Annual Meeting
HSMN NewsFeed - 9 Nov 2006
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
Targacept Announces Positive Results of Phase II Clinical Trial in Major Depression
HSMN NewsFeed - 19 Jul 2006
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program for the Treatment of Insomnia
Somaxon Pharmaceuticals Provides Update on SILENOR(TM) Development Program for the Treatment of Insomnia
HSMN NewsFeed - 18 Jul 2006
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
Valeant Pharmaceuticals Announces Availability of Zelapar(R) for Parkinson's Disease Patients
HSMN NewsFeed - 12 Jul 2006
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
Teva Will Be Sole Promoter of AZILECT(R) for Parkinson's Disease in the United States
HSMN NewsFeed - 29 Jun 2006
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
Noven Confirms Availability of Daytrana(TM) Methylphenidate Transdermal System
HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
HSMN NewsFeed - 22 May 2006
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
New Data Presented on the Effect of Cymbalta(R) on Sexual Function in Depressed Patients
HSMN NewsFeed - 22 May 2006
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
HSMN NewsFeed - 17 May 2006
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
AZILECT(R) FDA Approval Brings New Hope to People Living With Parkinson's Disease
HSMN NewsFeed - 17 May 2006
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
Teva Announces FDA Grants Approval of AZILECT(R) (Rasagiline) for Parkinson's Disease
HSMN NewsFeed - 15 May 2006
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
Clinical Data Announces Management Reorganization and Plan to Spin Off Vilazodone Business
HSMN NewsFeed - 9 May 2006
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Lilly Submits Cymbalta(R) Supplemental New Drug Application for Generalized Anxiety Disorder
Additional items found! 181

Members Archive contains
181 additional stories matching:
antidepressant
(Password required)
antidepressant
(Password required)